ImmuCell develops, manufactures and markets animal health biologics for calf health and cattle productivity. Its primary product line, First Defense, uses colostrum-derived, orally delivered antibodies to provide Immediate Immunity against principal viral and bacterial causes of scours in newborn dairy and beef calves.
Company announcements commonly address preliminary product sales, unaudited financial results, manufacturing efficiency, commercial expansion, and the strategic focus on the First Defense franchise. Other recurring developments include board composition, committee structure, senior employment agreements, and updates tied to the paused investment in Re-Tain and related asset use.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.